

Imre Pavo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3361247/publications.pdf>

Version: 2024-02-01

92
papers

3,591
citations

159585

30
h-index

149698

56
g-index

99
all docs

99
docs citations

99
times ranked

3456
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS). <i>Calcified Tissue International</i> , 2022, 110, 74-86.	3.1	8
2	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. <i>Cell Reports Medicine</i> , 2022, 3, 100477.	6.5	39
3	Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. <i>Bone</i> , 2022, 162, 116478.	2.9	4
4	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 80-90.	3.6	5
5	Hormone Replacement Therapy and Aging: A Potential Therapeutic Approach for Age-Related Oxidative Stress and Cardiac Remodeling. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-9.	4.0	7
6	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. <i>Diabetologia</i> , 2021, 64, 1982-1989.	6.3	44
7	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. <i>Diabetes</i> , 2021, 70, 2092-2106.	0.6	17
8	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. <i>Diabetes</i> , 2021, 70, 2683-2693.	0.6	26
9	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. <i>Diabetes Care</i> , 2021, 44, 511-518.	8.6	16
10	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 1811-1824.	13.7	257
11	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. <i>Genome Medicine</i> , 2020, 12, 109.	8.2	8
12	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. <i>EBioMedicine</i> , 2020, 58, 102932.	6.1	3
13	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. <i>PLoS Medicine</i> , 2020, 17, e1003149.	8.4	47
14	Distinct Approaches of Raloxifene: Its Far-Reaching Beneficial Effects Implicating the HO-System. <i>Biomolecules</i> , 2020, 10, 375.	4.0	2
15	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. <i>Diabetologia</i> , 2020, 63, 744-756.	6.3	12
16	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. <i>PLoS ONE</i> , 2020, 15, e0242360.	2.5	7
17	Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis. <i>Acta Diabetologica</i> , 2019, 56, 1169-1175.	2.5	6
18	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. <i>Diabetologia</i> , 2019, 62, 1601-1615.	6.3	22

#	ARTICLE	IF	CITATIONS
19	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. <i>Journal of Hepatology</i> , 2019, 71, 594-602.	3.7	23
20	Effect of once weekly dulaglutide by baseline beta cell function in people with type 2 diabetes in the AWARD programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2023-2028.	4.4	20
21	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>post hoc</i> analysis of the AWARD 2, 4 and 5 Trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1490-1498.	4.4	40
22	Effect of once weekly dulaglutide on glycated haemoglobin (<sc>HbA1c</sc>) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <sc>HbA1c</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 409-418.	4.4	56
23	Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>post hoc</i> analysis of the AWARD 2, 4 and 5 trials". <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2319-2320.	4.4	0
24	Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2230-2235.	2.8	10
25	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the <sc>AWARD</sc> programme. <i>Diabetic Medicine</i> , 2018, 35, 1434-1439.	2.3	59
26	Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. <i>Bone</i> , 2017, 95, 41-46.	2.9	47
27	Cardioprotective Effect of Selective Estrogen Receptor Modulator Raloxifene Are Mediated by Heme Oxygenase in Estrogen-Deficient Rat. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-9.	4.0	16
28	Teriparatide in patients with osteoporosis and type 2 diabetes. <i>Bone</i> , 2016, 91, 152-158.	2.9	68
29	Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. <i>Bone</i> , 2016, 89, 16-24.	2.9	20
30	Influence of Postprandial Hyperglycemic Conditions on Arterial Stiffness in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1134-1143.	3.6	28
31	Cardioprotective Effects of Voluntary Exercise in a Rat Model: Role of Matrix Metalloproteinase-2. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-9.	4.0	18
32	Endogenous Estrogen-Mediated Heme Oxygenase Regulation in Experimental Menopause. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-7.	4.0	30
33	Heme oxygenase contributes to estradiol and raloxifene-induced vasorelaxation in estrogen deficiency. <i>International Journal of Cardiology</i> , 2015, 189, 252-254.	1.7	7
34	Anti-Inflammatory Effect of Recreational Exercise in TNBS-Induced Colitis in Rats: Role of NOS/HO/MPO System. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-11.	4.0	41
35	Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density—The CONFORS Study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1777-1785.	2.8	39
36	Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy. <i>Osteoporosis International</i> , 2014, 25, 2709-2719.	3.1	21

#	ARTICLE	IF	CITATIONS
37	Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. <i>Bone</i> , 2014, 59, 139-147.	2.9	69
38	Sexual Dimorphism of Cardiovascular Ischemia Susceptibility Is Mediated by Heme Oxygenase. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-11.	4.0	27
39	Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice. <i>Current Medical Research and Opinion</i> , 2011, 27, 343-353.	1.9	3
40	Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 2027-2036.	3.1	55
41	Protective effect of ischaemic preconditioning on ischaemia/reper-fusion-induced microvascular obstruction determined by online measurements of coronary pressure and blood flow in pigs. <i>Thrombosis and Haemostasis</i> , 2010, 103, 450-460.	3.4	22
42	Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1998-2006.	2.8	69
43	Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries. <i>Coronary Artery Disease</i> , 2008, 19, 635-643.	0.7	7
44	Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. <i>Bone</i> , 2007, 41, 378-385.	2.9	141
45	Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. <i>Current Medical Research and Opinion</i> , 2007, 23, 2677-2687.	1.9	23
46	Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1173-1180.	2.8	72
47	The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 870-877.	3.6	37
48	Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: Prothrombotic response of drug-eluting or bare stent implantation within the first 24 hours. <i>Thrombosis and Haemostasis</i> , 2006, 96, 202-209.	3.4	17
49	Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3970-3977.	3.6	181
50	Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1. <i>Maturitas</i> , 2005, 52, 87-101.	2.4	15
51	Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo. <i>European Journal of Pharmacology</i> , 2004, 495, 179-184.	3.5	11
52	Synergistic interaction of endogenous platelet-activating factor and vasopressin in generating angina in rats. <i>European Journal of Pharmacology</i> , 2004, 498, 195-202.	3.5	8
53	Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 745-751.	2.8	437
54	Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 764-772.	2.8	104

#	ARTICLE	IF	CITATIONS
55	Raloxifene Treatment Is Associated With Increased Serum Estradiol and Decreased Bone Remodeling in Healthy Middle-Aged Men With Low Sex Hormone Levels. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1518-1524.	2.8	49
56	Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. <i>Fertility and Sterility</i> , 2004, 81, 132-136.	1.0	57
57	Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. <i>Osteoporosis International</i> , 2003, 14, 741-749.	3.1	29
58	Inhibitory effect of galanin on dopamine induced increased oxytocin secretion in rat neurohypophyseal tissue cultures. <i>Regulatory Peptides</i> , 2003, 116, 35-41.	1.9	10
59	Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.. <i>Bone</i> . 2003, 33, 293-300.	2.9	168
60	Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1637-1645.	3.6	154
61	Role of flanking sequences and phosphorylation in the recognition of the simian-virus-40 large T-antigen nuclear localization sequences by importin- α . <i>Biochemical Journal</i> , 2003, 375, 339-349.	3.7	102
62	Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 122-128.	3.6	50
63	Inhibitory effect of galanin on dopamine-induced enhanced vasopressin secretion in rat neurohypophyseal tissue cultures. <i>Regulatory Peptides</i> , 2002, 110, 17-23.	1.9	13
64	Mood effect of raloxifene in postmenopausal women. <i>Maturitas</i> , 2002, 42, 71-75.	2.4	55
65	Testosterone-secreting gonadotropin-responsive adrenal adenoma and its treatment with the antiandrogen flutamide. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 622-627.	3.3	18
66	Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 280, R458-R465.	1.8	18
67	Endogenous bacteria-triggered inducible nitric oxide synthase activation protects the ovariectomized rat stomach. <i>Journal of Physiology (Paris)</i> , 2001, 95, 137-140.	2.1	4
68	Vasopressin deficiency decreases the frequency of gastroduodenal ulceration in humans. <i>Journal of Physiology (Paris)</i> , 2000, 94, 63-66.	2.1	3
69	Nitric oxide-mediated mucus hypersecretion protects the stomach of ovariectomized rats. <i>European Journal of Pharmacology</i> , 2000, 392, R5-R7.	3.5	3
70	Interactions of pro-inflammatory and vasoactive mediators with nitric oxide in the regulation of rat vascular permeability during laparotomy. <i>European Journal of Pharmacology</i> , 2000, 402, 193-197.	3.5	1
71	Raloxifene, an oestrogen receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. <i>European Journal of Pharmacology</i> , 2000, 410, 101-104.	3.5	25
72	Estrogen-mediated up-regulation of the Ca-dependent constitutive nitric oxide synthase in the rat aorta and heart. <i>Life Sciences</i> , 2000, 68, 49-55.	4.3	15

#	ARTICLE	IF	CITATIONS
73	Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 667-672.	2.2	20
74	Nitric oxide modulates the gastrointestinal plasma extravasation following intraabdominal surgical manipulation in rats. <i>European Journal of Pharmacology</i> , 1999, 375, 211-215.	3.5	5
75	Detrimental effects of oestradiol on cysteamine-induced gastroduodenal ulceration in the female rat. <i>Journal of Physiology (Paris)</i> , 1999, 93, 491-494.	2.1	6
76	Adenoviruses synergize with nuclear localization signals to enhance nuclear delivery and photodynamic action of internalizable conjugates containing chlorin e6. , 1999, 81, 734-740.		43
77	Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat. <i>European Journal of Pharmacology</i> , 1998, 352, 257-261.	3.5	31
78	Nuclear Targeting of Chlorin e6 Enhances Its Photosensitizing Activity. <i>Journal of Biological Chemistry</i> , 1997, 272, 20328-20331.	3.4	109
79	Effects of testosterone on the rat renal medullary vasopressin receptor concentration and the antidiuretic response. <i>Life Sciences</i> , 1995, 56, 1215-1222.	4.3	20
80	Aggressive role of vasopressin in development of different gastric lesions in rats. <i>European Journal of Pharmacology</i> , 1994, 258, 15-22.	3.5	30
81	Lateral mobility of the antagonist-occupied V2 vasopressin receptor in membranes of renal epithelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1223, 240-246.	4.1	12
82	Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 255-259.	6.4	10
83	Oxytocin induced cAMP-dependent protein kinase activation and urokinase-type plasminogen activator production in LLC-PK1renal epithelial cells is mediated by the vasopressin V2-receptor. <i>FEBS Letters</i> , 1993, 315, 134-138.	2.8	10
84	Synthesis and binding characteristics of two sulfhydryl-reactive probes for vasopressin receptors. <i>FEBS Letters</i> , 1993, 316, 59-62.	2.8	5
85	Lack of Interaction of Vasopressin with its Antisense Peptides: A Functional and Immunological Study. <i>Journal of Receptors and Signal Transduction</i> , 1993, 13, 881-902.	1.2	10
86	New oxytocin antagonists containing sarcosine at position 7. , 1993, , 702-703.		0
87	Conformation of [8-arginine]vasopressin and V1 antagonists in dimethyl sulfoxide solution derived from two-dimensional NMR spectroscopy and molecular dynamics simulation. <i>FEBS Journal</i> , 1991, 201, 355-371.	0.2	48
88	Somatostatin ₂₈₍₁₅₋₂₈₎ , but not somatostatin ₂₈₍₁₋₁₂₎ , affects central monoaminergic neurotransmission in rats. <i>Neuropeptides</i> , 1990, 16, 181-186.	2.2	12
89	Differential inactivation of vasopressin receptor subtypes in isolated membranes and intact cells by N-ethylmaleimide. <i>FEBS Letters</i> , 1990, 272, 205-208.	2.8	20
90	Comparative studies of somatostatin-14 and some of its fragments on passive avoidance behavior, open field activity and on barrel rotation phenomenon in rats. <i>Peptides</i> , 1989, 10, 1153-1157.	2.4	22

#	ARTICLE	IF	CITATIONS
91	Protective effect of an orally administered, highly potent somatostatin analog (RC-121) against absolute ethanol-induced hemorrhagic erosions of the rat gastric mucosa. Life Sciences, 1989, 44, 1573-1578.	4.3	12
92	The effects of somatostatin and some of its tetrapeptide fragments on ethanol-induced gastric mucosal erosion in rat. Life Sciences, 1987, 41, 1123-1126.	4.3	7